Clinical trials: Sars-CoV2
Corona Virus Infection
Trial of Treatments for COVID-19 in Hospitalized Adults
DisCoVeRy is a randomized controlled trial among adults (≥18-year-old) hospitalized for COVID-19. This study is an adaptive, randomized, open or blinded, depending on the drug to be evaluated, clinical trial to evaluate the…
- Trial name
- DisCoVeRy (NCT04315948)
- Testing
- Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A
- Where
- 62 sites in Austria, Belgium and 5 more
- Volunteers
- 1,552 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
SARS-CoV2 Infection, SARS-CoV2 Antibodies
Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study
Great expectations to control the pandemic are placed in vaccines against COVID-19. Currently, the four COVID-19 vaccines approved in the European Union.
- Trial name
- DANTE-SIRIO 7 (NCT05109585)
- Testing
- assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule, assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule
- Where
- Poland
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Collegium Medicum w Bydgoszczy
COVID-19 Pandemic
Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.
Taking a regional hospital as an example, the investigators will discuss the changes in the community cumulative incidence rate(CIR) and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak.
- Trial name
- NCT05236309
- Testing
- Jing-Guan-Fang(JGF) : Chinese herbal decoction
- Where
- Taiwan
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Taipei City Hospital
Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2
Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19
The COVID-19 pandemic has had a dramatic effect in public health worldwide. In Brazil, there have been more than 2 million confirmed cases and over 75,000 deaths since February 26, 2020.
- Trial name
- RUXO-COVID (NCT04477993)
- Testing
- Janus Kinase Inhibitor (ruxolitinib)
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- Vanderson Geraldo Rocha
Disabilities Multiple
Improving the Health and Social Participation of People With Disabilities From Underrepresented Groups Post COVID
This is a single-arm community-based feasibility study examining recruitment, retention, adherence, and satisfaction with ENGAGE, a community-based intervention designed to address pandemic-related social isolation among people…
- Trial name
- NCT05792852
- Testing
- ENGAGE
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Illinois at Chicago
Post-acute Covid-19 Syndrome
Homeopathic Treatment of Post-acute COVID-19 Syndrome
To determine whether an individually prescribed homeopathic medicine has an effect greater than a placebo and is a viable treatment option to improve fatigue and quality of life for patients suffering from the symptoms of…
- Trial name
- NCT05104749
- Testing
- Homeopathic Medication
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Southwest College of Naturopathic Medicine
Pneumococcal Disease, COVID-19
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT04887948
- Testing
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Where
- 27 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine
This was a randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the safety and immunogenicity of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen)…
- Trial name
- NCT05175625
- Testing
- SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Cinnagen
COVID-19
CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany
This is a multicenter, observational, prospective, epidemiological cohort study at 45 hospitals in Germany, all part of a German hospital network. All hospitalized patients tested positive for SARS-CoV-2 will be included.
- Trial name
- CORONA Germany (NCT04659187)
- Where
- 8 sites in Germany
- Volunteers
- 4,000 people
- Sponsor
- Asklepios proresearch
SARS-CoV-2 Infection, Acute Kidney Injury
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+)…
- Trial name
- NIRVANA (NCT04818216)
- Testing
- Nicotinamide riboside
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
COVID-19
Evaluation of the Immune Response to SARS-CoV-2 Among Patients With Covid-19 in Costa Rica
Describe the immune response of patients affected by SARS-CoV-2, including an assessment of the types of antibodies elicited by the infection, specifc antibody titers for the different isotypes, evolution of the antibody response…
- Trial name
- RESPIRA (NCT04537338)
- Testing
- 1. Characterize the immune response after infection with SARS-CoV-2
- Volunteers
- 2,000 people
- Sponsor
- Agencia Costarricense de Investigaciones Biomedicas
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
- Trial name
- NCT05375838
- Testing
- mRNA-1073, mRNA-1010, mRNA-1273
- Where
- 14 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Acute Pancreatitis, 2019 Novel Coronavirus Infection
Study and Analysis of Acute Pancreatitis Complicated With COVID-19
The goal of this observational study was to explore the complex relationship between changes in the intestinal microbiome and serum metabolites in patients with novel coronavirus infection and acute pancreatitis.
- Trial name
- NCT05722678
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yuansong Sun
Covid19
Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel
The purpose of this trial is to assess the effect of immunotherapy with the bacterial preparation MV130 on the spread and course of SARS-CoV-2 infection in highly exposed subjets, as is the case with healthcare personnel.
- Trial name
- Bacmune (NCT04452643)
- Testing
- BACMUNE (MV130)
- Where
- 3 sites in Mexico
- Sponsor
- Inmunotek S.L.
COVID-19, COVID-19 Immunisation
Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
This is a phase 1, open-label, randomized clinical trial in males and non-pregnant females, 18 years of age and older, who are in good health, have no known history of COVID-19 or SARS-CoV-2 infection, and meet all other…
- Trial name
- NCT04785144
- Testing
- mRNA-1273, mRNA-1273.351
- Where
- 4 sites in United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hypertension, Pulmonary, Right Ventricular Overload
The Prevalence of Pulmonary Hypertension in Patients With COVID-19.
The virus infection Covid-19 fills our hospitals and intensive care departments in a very unique way and there is a lack of essential insight into the pathophysiology of the disease.
- Conditions
- Hypertension, Pulmonary, Right Ventricular Overload, COVID
- Trial name
- NCT04459364
- Where
- Sweden
- Volunteers
- 67 people
- Sponsor
- Attgeno AB
SARS-CoV-2, COVID-19
eVusheld Assessment reaL wORld Effectiveness at UPMC
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR-C19 UPMC (NCT05667116)
- Testing
- EVUSHELD
- Where
- United States
- Volunteers
- 4,232 people
- Sponsor
- AstraZeneca
Covid 19
Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19
The RT-PCR on rhino-pharynge sampling highlights the genetic material of the virus and indicates that a subject is infected with SARS-CoV-2.
- Trial name
- EliSpot (NCT04418206)
- Testing
- patients COVID 19
- Where
- 4 sites in France
- Volunteers
- 950 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Long COVID
DAOIB for the Treatment of Brain Fog
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks.
- Trial name
- NCT05764538
- Testing
- DAOIB
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
COVID-19
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.
- Trial name
- NCT04343755
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Hackensack Meridian Health